-

CG Life Named to the 2026 Inc. 5000 List of America’s Fastest-Growing Private Companies

Recognition reflects sustained growth, strategic expansion, and continued investment in the future of life science communications

CHICAGO & SAN DIEGO & NEW YORK--(BUSINESS WIRE)--CG Life, a specialized pharma agency built for the unique challenges of bringing therapies for rare, specialty, and hard-to-treat diseases to market, has been named to the 2026 Inc. 5000, an annual ranking of the fastest-growing private companies in America.

The national honor recognizes CG Life for its continued business growth and significant expansion of its role as a commercialization partner for biopharma companies. Last month, CG Life combined with AI-native pharma agency, The Considered+AI. The union brings together deep scientific and commercialization expertise, an AI-native operating model, and world-class talent to help clients bring breakthrough therapies to market with greater speed, precision, and impact.

“This recognition by Inc. alongside so many of the country’s most dynamic, high-growth companies is a testament to the talented people at CG Life who bring their best every day,” said David Ormesher, CEO of CG Life. “Our industry is changing quickly. Science and technology are moving faster, product launches are getting more complex, and our clients need tighter relationships with their agency partners. We’ve been very deliberate about where we invest and the kind of company we’re building, so this honor from Inc. is a validation that we’re on the right path.”

CG Life’s growth story has been written over the past two decades of helping biopharma and life sciences companies translate complex science into meaningful commercial outcomes. The agency has developed deep expertise across rare and hard-to-treat diseases, where small, highly informed communities, complex science, and the need for strong evidence require a different approach to commercialization.

The addition of The Considered+AI further advances that strategy. CG Life is a modern commercialization partner designed to help clients move faster from insight to action while connecting more effectively with patients, caregivers, healthcare professionals, and advocacy communities.

Published annually by Inc., the Inc. 5000 recognizes the nation‘s most successful independent businesses based on percentage revenue growth over a three-year period. Companies appearing on the list have demonstrated remarkable resilience, innovation, and sustained expansion despite changing economic conditions.

About CG Life

Founded in 2003, CG Life is a specialized pharma agency built for the unique challenges of bringing therapies for rare and hard-to-treat diseases to market, where traditional commercialization models often fall short. CG Life partners with biopharma companies to navigate the complexities of rare disease commercial launches by combining deep scientific expertise, strategy-led activation of physician and patient communities, and results-driven engagement to support what’s best for patients. The result is faster, more effective launches in markets where insight, creativity, and credibility determine success. Begin your journey at CGLife.com.

Contacts

Media Contact
Erik Clausen
Managing Director, Strategic Communications Group
CG Life
eclausen@cglife.com

CG Life

Details
Headquarters: Chicago, Illinois
CEO: David Ormesher
Employees: 150
Organization: PRI

Release Versions

Contacts

Media Contact
Erik Clausen
Managing Director, Strategic Communications Group
CG Life
eclausen@cglife.com

More News From CG Life

Inaugural 24/364 Rare Disease Film Festival to Bring Advocacy, Media and Film Together to Shine a Light on Rare Disease

CHICAGO & NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Sponsored by CG Life, the inaugural 24/364 Rare Disease Film Festival aims to elevate the voices of people living with rare diseases through the power of storytelling. Taking place March 11-12, 2027, at the San Diego Natural History Museum in Balboa Park, the Festival will feature film screenings, filmmaker Q&As, panels and discussions with thought leaders, receptions, and networking. To date, 97 films have been submitted from 33 countries fo...

New 24/364 Film “Dylan Findling” Captures One Family’s Refusal to Let a Rare Disease Define Their Son’s Life

CHICAGO & NEW YORK & SAN DIEGO--(BUSINESS WIRE)--Dylan Findling, a powerful new short documentary from 24/364, debuts today as the second film in the In the Light series, offering an intimate look at the life of Dylan Findling and his family determined to keep living, hoping and fighting in the face of a devastating rare disease diagnosis.At nine years old, Dylan was an active kid who loved basketball, drawing, and spending time outside. Then his family learned that he had adrenoleukodystrophy (...

CG Life Combines With AI-Native Agency The Considered+AI to Create a New Model of Commercialization Partner

CHICAGO & NEW YORK & SAN DIEGO--(BUSINESS WIRE)--CG Life, a specialized pharma agency built for the unique challenges of bringing therapies for rare, specialty, and hard-to-treat diseases to market, has combined with The Considered+AI, an AI-native agency built from inception for the era of generative AI. The union blends CG Life’s rare disease and precision medicine expertise with The Considered’s proven approach to amplifying world-class talent through AI to commercialize therapies with great...
Back to Newsroom